Overview

Detailed Summary

Kopran Limited is an integrated pharmaceutical company engaged in the manufacture and sale of formulations and active pharmaceutical ingredients (APIs) globally, with a focus on quality and technology. They operate two main business verticals through Kopran Limited and Kopran Research Laboratories Ltd.
Kopran has experienced fluctuating financial performance, with revenue from operations in Q3 2025-26 reaching Rs. 19,428 lakhs. However, EBITDA margins have decreased compared to previous years, indicating potential cost pressures or market competition.
The company has an extensive export reach across over 50 countries and has facilities accredited by international regulatory bodies, underscoring its commitment to maintaining global manufacturing standards.
Strategically, Kopran focuses on driving sustainable growth through R&D, capacity expansion, and reducing dependency on imports for intermediates, enhancing domestic self-sufficiency.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 960 Cr
Volatility: High Risk
P/E Ratio: 37.3
Industry P/E: 36.7
PEG Ratio: -1.1
P/B Ratio: 1.8
52W High: 218.90
52W Low: 107.00

Sales CAGR

1Y: 2.44%
3Y: 9.84%
5Y: 8.61%
10Y: 4.19%

Profit CAGR

1Y: -24.35%
3Y: 31.75%
5Y: 19.07%
10Y: 9.95%

ROE

TTM: 4.85%
3Y: 8.06%
5Y: 11.29%
10Y: 11.75%

ROCE

TTM: 6.56%
3Y: 11.57%
5Y: 15.54%
10Y: 16.36%

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
BAJAJHCARE		325.35	1,087 Cr	19.32	2.04	0.46	8.81	10.79	1.91
THEMISMED		110.10	1,014 Cr	611.67	2.77	0.45	0.42	2.70	0.19
BPLPHARMA		1426.00	990 Cr	—	3.07	0.07	-2.54	-1.83	-4.45
SIGACHI		25.43	972 Cr	28.57	1.86	0.39	6.52	6.49	-9.84
KOPRAN		197.25	960 Cr	37.32	1.81	1.51	4.85	6.56	2.83
REMUS		719.60	848 Cr	22.92	2.42	0.07	10.54	16.04	7.98
SGRL		646.00	825 Cr	46.49	5.07	0.00	10.90	14.23	8.56
Median: 7 Co.	—	325.35	972 Cr	32.95	2.42	0.39	6.52	6.56	1.91

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	159	186	139	152	166	172	135	118	194	234
Expenses	135	164	121	137	146	155	121	123	177	201
Operating Profit	24	22	18	15	20	17	14	-5.28	18	33
OPM %	14.84	11.66	13.02	9.72	11.93	9.91	10.46	-4.48	9.15	14.08
Other Income	2.43	9.67	2.63	1.00	0.17	3.26	2.56	0.03	0.07	0.09
Interest	2.24	2.59	2.18	2.23	2.16	2.77	2.54	2.09	2.67	3.17
Depreciation	3.27	3.59	3.87	3.85	4.00	3.87	4.26	4.28	4.42	4.52
Profit Before Tax	21	25	15	9.64	14	14	9.89	-12	11	25
Tax %	22.96	26.05	24.71	23.44	24.96	29.39	24.67	14.62	13.04	25.56
Net Profit	16	19	11	7.38	10	9.68	7.45	-9.92	9.34	19
EPS in Rs	3.27	3.84	2.30	1.53	2.15	2.01	1.54	-2.06	1.93	3.91

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales	319	315	358	359	492	478	551	615	630	625
Expenses	274	283	312	313	410	390	499	540	557	560
Operating Profit	45	32	46	47	82	87	52	74	73	66
OPM %	14.12	10.10	12.95	12.99	16.63	18.30	9.40	12.11	11.58	10.52
Other Income	11	9.60	3.06	0.08	18	11	3.07	15	3.98	6.99
Interest	14	8.60	8.99	8.91	6.24	5.12	6.08	8.59	9.34	9.70
Depreciation	8.33	8.51	8.74	9.58	10	11	13	13	16	16
Profit Before Tax	25	23	32	28	83	82	36	68	52	47
Tax %	19.58	10.48	24.13	25.68	26.07	25.37	24.49	24.56	25.79	25.88
Net Profit	20	20	24	21	62	61	27	51	39	35
EPS in Rs	4.11	4.25	4.97	4.33	12.76	12.69	5.65	10.54	7.98	5.32
Dividend Payout %	0.00	0.00	0.00	0.00	21.07	21.79	53.10	28.38	37.55	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	43	43	43	43	43	43	48	48	48	48
Reserves	57	81	101	125	146	202	378	391	443	470
Borrowings	75	89	82	87	78	64	75	75	99	148
Other Liabilities	88	85	89	97	104	130	110	135	153	178
Total Liabilities	264	298	315	352	371	439	611	650	743	844
Fixed Assets	101	104	104	113	111	112	151	165	182	208
CWIP	3.13	6.29	9.93	24	30	43	36	70	97	113
Investments	0.11	0.05	0.05	0.02	0.02	0.05	0.06	0.06	0.06	0.06
Other Assets	160	187	201	215	230	284	425	415	465	522
Total Assets	264	298	315	352	371	439	611	650	743	844

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	29	16	26	25	31	60	-33	34	43	42
Cash from Investing Activity	-9.07	-18	-11	-25	-13	-25	-84	-13	-44	-56
Cash from Financing Activity	-19	1.97	-15	-0.58	-18	-35	123	-20	0.99	26
Net Cash Flow	0.22	-0.12	-0.21	-0.03	0.42	0.10	4.93	1.53	0.69	11

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	44.49%	44.49%	44.49%	44.49%	44.49%	44.46%	44.42%	44.42%	44.42%	44.42%	44.42%	44.42%
FIIs	0.39%	0.48%	0.84%	0.68%	1.32%	0.86%	1.12%	0.76%	0.60%	0.36%	0.57%	0.51%
DIIs	0.35%	0.14%	1.20%	0.14%	0.22%	0.00%	0.00%	0.01%	0.01%	0.01%	0.00%	0.01%
Public	54.77%	54.89%	53.47%	54.70%	53.97%	54.68%	54.45%	54.82%	54.98%	55.22%	55.00%	55.06%
Total Shareholders	53,791	51,636	50,850	51,492	57,154	60,560	58,652	60,194	62,222	60,886	58,639	56,925

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q1 FY25

Investor Presentation

Q4 FY24

Showing 1 - 8 of 16

Actions

Action Type

‌
‌

Announcements

Last 7 days

Sentiment

Board Meeting

3 days ago

Kopran Ltd Board Meeting on Aug 07, 2026

Kopran Ltd: Board meeting scheduled for 2026-08-07 to consider and approve unaudited standalone and consolidated financial results for Q1 FY 2026-27; trading window to reopen after declaration.

Board Meeting

3 days ago

Kopran Ltd Board Meeting on August 07, 2026

Kopran Ltd informed exchanges that its Board will meet on 2026-08-07 to consider and approve unaudited standalone and consolidated financial results for Q1 ended June 30, 2026; trading window to reopen after results.

Regulatory/Compliance Filing

5 days ago

Kopran Ltd: Newspaper Publication on NCLT Scheme

Kopran Ltd published Form CAA-3 public notices per NCLT direction about the Scheme of Amalgamation of Kopran Laboratories Limited with Kopran Limited; NCLT hearing fixed for 2026-08-05.

Public Notice/Press Release

5 days ago

Kopran Ltd: Newspaper Publication — Scheme Notice

Kopran Ltd published newspaper ads (Form CAA-3) per NCLT directions for the Scheme of Amalgamation of Kopran Laboratories Limited with Kopran Limited; NCLT hearing fixed for 2026-08-05.

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Kopran Ltd

Kopran Ltd (KOPRAN) is currently trading at 197.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Kopran Limited is an integrated pharmaceutical company engaged in the manufacture and sale of formulations and active pharmaceutical ingredients (APIs) globally, with a focus on quality and technology. They operate two main business verticals through Kopran Limited and Kopran Research Laboratories Ltd. Kopran has experienced fluctuating financial performance, with revenue from operations in Q3 2025-26 reaching Rs. 19,428 lakhs. However, EBITDA margins have decreased compared to previous years, indicating potential cost pressures or market competition. The company has an extensive export reach across over 50 countries and has facilities accredited by international regulatory bodies, underscoring its commitment to maintaining global manufacturing standards. Strategically, Kopran focuses on driving sustainable growth through R&D, capacity expansion, and reducing dependency on imports for intermediates, enhancing domestic self-sufficiency.

Over the past 52 weeks, Kopran Ltd has traded between a low of ₹107.00 and a high of ₹218.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Kopran Ltd has a market capitalization of approximately 960.40. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Kopran Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 37.32 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 960.40 Cr, Kopran Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Kopran Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Kopran Ltd is 37.32. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Kopran Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison